An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose of BAY 1251152 in patients with advanced cancer
A study for patients with advanced cancer using study drug BAY 1251152
Sponsor: Bayer
Enrolling: Male and Female Patients
IRB Number: AAAQ4758
U.S. Govt. ID: NCT02635672
Contact: Emerson Lim, MD: 646-317-6041 / el2342@cumc.columbia.edu
Additional Study Information: The purpose of the study is to evaluate the safety and tolerability of BAY 1251152 in patients with any type of solid tumors or non-indolent non-hodgkins lymphoma. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.
This study is closed
Investigator
Emerson Lim, MD
Do You Qualify?
Have you been diagnosed with advanced solid tumors or non Hodgkin's Lymphoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Emerson Lim, MD
el2342@cumc.columbia.edu
646-317-6041
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE